Health Economics›Chronic lymphocytic leukemia›First-line therapy non-randomized or retrospective data

First-line therapy non-randomized or retrospective data

Chronic lymphocytic leukemia · 15 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
PCO Variant #01 Partial	—	R 1 178 513	21d	—	—	~6	~R 3 228 591 indirect	—
Alemtuzumab and Methylprednisolone Variant #01	—	R 588 515	28d	—	—	~4	~R 1 186 004 indirect	—
O-FC Variant #02	—	R 426 746	28d	~28.9 mo	—	~5	~R 1 485 170 PFS proxy · indirect	1
AVO Variant #01	—	R 317 806	28d	—	—	~8	~R 1 260 738 indirect	—
HDMP-R Variant #02	—	R 235 835	28d	—	—	~3	~R 344 838 indirect	—
iFCR Variant #01	—	R 160 416	28d	—	—	~7	~R 787 033 indirect	—
CFAR Variant #01	—	R 133 216	28d	—	—	~6	~R 643 866 indirect	—
G-FC Variant #01	—	R 112 275	28d	—	—	~5	~R 241 432 indirect	—
Lenalidomide and Rituximab (R2) Variant #08	—	R 106 523	28d	~39.4 mo	—	~13	~R 141 371 PFS proxy · indirect	5
PCR Variant #03 Partial	—	R 103 769	28d	—	—	~6	~R 208 140 indirect	—
Bendamustine and Obinutuzumab Variant #02	—	R 101 593	28d	—	—	~6	~R 227 981 PFS proxy · indirect	2
R-CC Variant #01	—	R 71 952	28d	—	—	~6	~R 276 286 indirect	—
Ruxolitinib monotherapy Variant #06 Partial	—	R 48 520	—	—	—	~1	~R 48 520 PFS proxy · indirect	2
Rituximab monotherapy Variant #09 Partial	—	—	28d	~53.2 mo	—	~1	—	5
Zanubrutinib and Obinutuzumab Partial	—	—	—	—	—	—	—	—

15 of 15 regimens shown